+

PE20070363A1 - Complejos metalicos con contenido de perfluoroalquilo como medios de contraste en imagenes de resonancia magnetica y procedimientos para su preparacion - Google Patents

Complejos metalicos con contenido de perfluoroalquilo como medios de contraste en imagenes de resonancia magnetica y procedimientos para su preparacion

Info

Publication number
PE20070363A1
PE20070363A1 PE2006000845A PE2006000845A PE20070363A1 PE 20070363 A1 PE20070363 A1 PE 20070363A1 PE 2006000845 A PE2006000845 A PE 2006000845A PE 2006000845 A PE2006000845 A PE 2006000845A PE 20070363 A1 PE20070363 A1 PE 20070363A1
Authority
PE
Peru
Prior art keywords
formula
methyl
magnetic resonance
complex
perfluoroalkyl
Prior art date
Application number
PE2006000845A
Other languages
English (en)
Inventor
Heiko Schirmer
Hanns-Joachim Weinmann
Johannes Platzek
Ludwig Zorn
Bernd Misselwitz
Jorg Meding
Heribert Schmitt-Willich
Thomas Brumby
Original Assignee
Schering Ag
Epix Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102005033903A external-priority patent/DE102005033903B4/de
Application filed by Schering Ag, Epix Pharm Inc filed Critical Schering Ag
Publication of PE20070363A1 publication Critical patent/PE20070363A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE R ES UN MONO U OLIGOSACARIDO OPCIONALMENTE PERALQUILADO, COMPLEJOS K DE FORMULA (II), (IV), ENTRE OTROS; Q ES UN ENLACE DIRECTO, ?-(CH2)m-?, ENTRE OTROS, DONDE ? Y ? SON SITIOS DE UNION; Rf ES UNA CADENA DE CARBONOS PERFLUORADA DE FORMULA CnF2nE, DONDE E ES F, Cl, Br, I O H; n ES DE 4 A 30; X ES UN COMPUESTO DE FORMULA (XI) DONDE G ES -O- O -SO2-; s Y s' SON 1 O 2; t ES 0 O 1; ? Y ? SON SITIOS DE UNION; K ES UN COMPLEJO METALICO DE FORMULA (II), (IV), ENTRE OTROS, DONDE R1 ES H O UN EQUIVALENTE DE IONES METALICOS DE NUMEROS ATOMICOS 21-29, 31-33, ENTRE OTROS; R2 Y R3 SON ALQUILO(C1-C7), BENCILO, ENTRE OTROS; U ES FENILENO, ALQUILENO(C1-C12), ENTRE OTROS; L ES UN COMPUESTO DE FORMULA (IXa), (IXc), ENTRE OTROS, DONDE ?, ? Y ? SON SITIOS DE UNION; A ES UNA CADENA DE CARBONOS (C1-C15). SON COMPUESTOS PREFERIDOS: COMPLEJO DE GADOLINIO DE 6-N-[1,4,7-TRIS-(CARBOXILATOMETIL)-1,4,7,10-TETRAAZACICLODODECAN-10-N-(PENTANOIL-3-AZA-4-OXO-5-METIL-5-IL)]-2-N-(1-O-?-d-CARBONILMETILMANOPIRANOSA)-L-LISIN-[(1H,1H,2H,2H-PERFLUORODECIL)-METIL]-AMIDA, COMPLEJO DE GADOLINIO DE 6-N-[1,4,7-TRIS-(CARBOXILATOMETIL)-1,4,7,10-TETRAAZACICLODODECAN-10-N-(PENTANOIL-3-AZA-4-OXO-5-METIL-5-IL)]-2-N-(1-O-?-d-CARBONILMETILMANOPIRANOSA)-L-LISIN-[(1H,1H,2H,2H-PERFLUOROOCTIL)-METIL]-AMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON UTILES PARA EL DIAGNOSTICO POR RESONANCIA MAGNETICA, RAYOS X
PE2006000845A 2005-07-15 2006-07-14 Complejos metalicos con contenido de perfluoroalquilo como medios de contraste en imagenes de resonancia magnetica y procedimientos para su preparacion PE20070363A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005033903A DE102005033903B4 (de) 2005-07-15 2005-07-15 Perfluoralkylhaltige Komplexe, Verfahren zu deren Herstellung, sowie deren Verwendung und diese enthaltende pharmazeutische Mittel
EP05090230 2005-08-10

Publications (1)

Publication Number Publication Date
PE20070363A1 true PE20070363A1 (es) 2007-04-20

Family

ID=38813200

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000845A PE20070363A1 (es) 2005-07-15 2006-07-14 Complejos metalicos con contenido de perfluoroalquilo como medios de contraste en imagenes de resonancia magnetica y procedimientos para su preparacion

Country Status (10)

Country Link
US (1) US20070020183A1 (es)
EP (1) EP1904462A2 (es)
JP (1) JP2009509915A (es)
CA (1) CA2615434A1 (es)
DO (1) DOP2006000166A (es)
GT (1) GT200600314A (es)
PE (1) PE20070363A1 (es)
TW (1) TW200740777A (es)
UY (1) UY29663A1 (es)
WO (1) WO2007009637A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618957B2 (en) * 2005-07-15 2009-11-17 Bayer Schering Pharma Aktiengesellschaft Perfluoroalkyl-containing complexes, process for their production as well as their use
DE102007015598A1 (de) * 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren
US7810965B2 (en) 2008-03-02 2010-10-12 Lumenetix, Inc. Heat removal system and method for light emitting diode lighting apparatus
US7969075B2 (en) 2009-02-10 2011-06-28 Lumenetix, Inc. Thermal storage system using encapsulated phase change materials in LED lamps
US8760265B2 (en) * 2009-05-08 2014-06-24 Apple Inc. Remote control signal learning and processing by a host device and accessory
CN105189448B (zh) * 2013-05-09 2017-05-24 佳能株式会社 化合物，光固化性组合物，和通过使用所述光固化性组合物的图案化膜、光学组件、电路板、电子组件的制造方法，和固化物
CN117603148A (zh) 2017-05-05 2024-02-27 探针技术开发及商业化中心 双官能螯合物的药代动力学增强及其用途
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
CN110891614A (zh) 2017-05-05 2020-03-17 融合制药公司 Igf-1r单克隆抗体及其用途
CN114181164A (zh) * 2021-12-13 2022-03-15 武汉大学中南医院 基于Fe(Ⅱ)特异性MRI对比剂的合成方法及其应用
CN114085619B (zh) * 2021-12-23 2022-07-15 泰州亚德胶粘制品有限公司 一种耐高温低粘着光学胶粘剂及其制备方法
CN115308319A (zh) * 2022-06-28 2022-11-08 北京大学 一种全氟及多氟烷基化合物非靶向筛查的定量方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641797B2 (en) * 2000-08-11 2003-11-04 Schering Aktiengesellschaft Perfluoroalkyl-containing complexes with sugar radicals, process for their production and their use
DE10040381C1 (de) * 2000-08-11 2002-06-06 Schering Ag Perfluoralkylhaltige Komplexe mit Zuckerresten, Verfahren zu deren Herstellung und ihre Verwendung
US6676928B2 (en) * 2000-08-11 2004-01-13 Schering Aktiengesellschaft Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use
US6818203B2 (en) * 2000-08-11 2004-11-16 Schering Aktiengesellschaft Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses
DE10040858C2 (de) * 2000-08-11 2003-12-18 Schering Ag Perfluoralkylhaltige Komplexe mit polaren Resten, Verfahren zu deren Herstellung und ihre Verwendung
US7334704B1 (en) * 2005-01-25 2008-02-26 William C Bynum Apparatus for flattening the walls of flexible tubes
US7618957B2 (en) * 2005-07-15 2009-11-17 Bayer Schering Pharma Aktiengesellschaft Perfluoroalkyl-containing complexes, process for their production as well as their use

Also Published As

Publication number Publication date
GT200600314A (es) 2007-07-05
US20070020183A1 (en) 2007-01-25
WO2007009637A3 (de) 2007-05-10
DOP2006000166A (es) 2007-02-28
CA2615434A1 (en) 2007-01-25
WO2007009637A2 (de) 2007-01-25
EP1904462A2 (de) 2008-04-02
JP2009509915A (ja) 2009-03-12
UY29663A1 (es) 2007-02-28
TW200740777A (en) 2007-11-01

Similar Documents

Publication Publication Date Title
PE20070363A1 (es) Complejos metalicos con contenido de perfluoroalquilo como medios de contraste en imagenes de resonancia magnetica y procedimientos para su preparacion
NO20064011L (no) Kontrastmidler for myokardial perfusjonsbilleddannelse
ES2525932T3 (es) Derivados de dihidrotetrabenazina radiomarcados y su uso como agentes de imagenología
NO20065048L (no) Kontrastmidler for myocardial perfusjonsbilleddannelse.
TW200608969A (en) Heterocyclic boronic acid compounds
RU2014112319A (ru) Соединения и фармацевтические композиции для лечения вирусных инфекций
EA200701799A1 (ru) Транс-каротиноиды, синтез указанных каротиноидов, получение композиций и их применение
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
EA200800848A1 (ru) Тиазолы в качестве фунгицидных средств
CU20100200A7 (es) Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
MX342806B (es) Compuestos y método para reducir el ácido úrico.
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
ATE552246T1 (de) Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten
AR073922A1 (es) 2- oxoquinoxalinas como bloqueadores de los canales de sodio tardios
RU2011108837A (ru) Новый способ и применение несимметрично мезозамещенных порфиринов и хлоринов для фдт
PE20081837A1 (es) Derivados de quinuclinidol como antagonistas de los receptores muscarinicos
MX2009002492A (es) Agentes que comprenden compuestos marcados con 18f y metodos relacionados.
RU2008130043A (ru) Комбинация, включающая комбретастатин и противораковые средства
EA200901142A1 (ru) 18f фторбензоильные меченые биологически активные соединения в качестве диагностических визуализирующих средств, а также бензотриазол-1-илоксибензоильные, 2,5-(диоксопирролидин-1-илокси)бензоильные и триметиламмониобензоильные предшественники
EA201070250A1 (ru) Противомикробный парентеральный состав
MX341173B (es) Proceso de fluorinado de derivados de anilida y derivados de fluorinado de benzotiazole en la forma de agentes de generacion de imagen in vivo.
RU2015122032A (ru) Оксазолидинонсодержащие соединения, композиции и способы их использования

Legal Events

Date Code Title Description
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载